PTOSB30 (07-09)
Approved for use through 07/31/2012, CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE. CMB 031-0331
U.S. Patient and Tradement Office, U.S. SEPARTIESE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control nurser.

Recuest

1		Application Numb	er 10	304,388
for Continued Examination (RCE) Transmittal		Filing Date	Jui	ne 4, 2007
		First Named Inve	ntor Ka	zunari HASEBE
Address to:		Art Unit	37	39
Mail Stop RCE Commissioner for Patents		Examiner Name	J. 1	Della
P.O. Box 1450 Alexandria, VA 22313-1450		Attorney Docket N	lumber 36	0882016200
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.				
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the U SPTO) on page 2.				
<ol> <li>Submission required under 37 CFR 1.14   Next: the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant drutes applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).</li> </ol>				
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.				
i Consider the arguments in the Appeal Brief or Reply Brief previously filed on				
ii. Other				
b. x Enclosed				
i. X Amendment/Reply iii. Information Disclosure Statement (IDS)				
iiAffidavit(s)/Declaration(s) ivOther				
2. Miscellaneous				
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a				
period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)				
b. Other				
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.				
a. X The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any Overpayments, to Deposit Account No. 03-1952				
i. X RCE fee required under 37 CFR 1.17(e)				
ii. X Extension of time fee (37 CFR 1.136 and 1.17)				
iii. Other				
b. Check in the amount of \$ enclosed				
c.   Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Signature (/aka		•	Date Sep	otember 22, 2011
Name (Print/Type)	Takamitsu Fujiu		Registration N	o. 63,971